
Journal Menu
► Journal MenuJournal Browser
► Journal BrowserSpecial Issue "Current and Future Bladder Cancer Landscape"
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 31 August 2023 | Viewed by 3144
Special Issue Editor
2. Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Sao Paulo 13087-571, Brazil
Interests: bladder cancer; diagnosis; prognosis; treatment; epidemiology
Special Issue Information
Dear Colleagues,
Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide, diagnosed as non-muscle invasive (NMIBC) in 75% of cases, in which cystoscopy, transurethral resection, and intravesical bacillus Calmette–Guérin (BCG) have withstood the test of time, remaining the gold standards, as well as neo-adjuvant cisplatin-based chemotherapy and cystectomy in the muscle-invasive context.
Since 2016, the bladder cancer treatment scenario has evolved with the introduction of monoclonal antibodies developed to specifically target immune checkpoint molecules, opening new diagnostic, prognostic, therapeutic, and epidemiological paradigms. This Special Issue will cover the present and future of this evolving landscape.
Prof. Dr. Leonardo O. Reis
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer
- diagnosis
- prognosis
- treatment
- epidemiology
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Assessment of the Ecological Association between Tobacco Smoking Exposure and Bladder Cancer Incidence over the Past Half-Century in the United States
Thomas Seisen, Muhieddine Labban, Stuart R. Lipsitz, Maxine Sun*, Quoc-Dien Trinh*
Abstract
Background: Tobacco smoking represents the most established risk factor for bladder cancer (BCa).
Objective: To assess the ecological association between tobacco smoking prevalence and BCa incidence in the US over the past half-century, and to contrast it with that observed for lung cancer (LCa).
Design, Setting and Participants: The annual overall tobacco smoking prevalence rates were extracted from the Report of the Surgeon General and the Center for Disease Control website for the years 1953-1983. The overall age-adjusted incidence rates of BCa and LCa were derived from the Surveillance, Epidemiology, and End Results database for the years 1983-2013 (30-year time-lag). All analyses were stratified according to gender.
Exposure: Tobacco smoking
Outcome Measurements and Statistical Analyses: Weighted least square regression models were used to assess the BCa and LCa incidence rate differences (IRD) related to tobacco smoking prevalence variations. Additional comparisons between the associations of tobacco smoking prevalence with BCa vs.LCa incidence rates were performed using a Wald test.
Results and limitations: The associations between tobacco smoking prevalence and BCa incidence were not significant in the overall (IRD=+0.04;95%CI=[from-0.14to+0.22];P=0.631), men (IRD=+0.07;95%CI=[from-0.09to+0.23];P=0.374) and women (IRD=+0.12;95%CI=[from-0.01to+0.25];P=0.061) populations. In contrast, the associations between tobacco smoking prevalence and LCa incidence were significant in the overall (IRD=+3.55;95%CI=[from+3.09to+4.00];P<0.001), men (IRD=+4.82;95%CI=[from+4.44to+5.20];P<0.001) and women (IRD=+3.55; 95%CI=[from+3.12to+3.99];P<0.001) populations. The difference between the observed associations of tobacco smoking prevalence with BCa vs.LCa incidence was significant in all examined populations (allP<0.001).
Conclusions: In contrast to LCa, we found that variations in tobacco smoking prevalence were not associated with the incidence trends of BCa in the US population over the past half-century.